KR20030068205A - 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법 - Google Patents
수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법 Download PDFInfo
- Publication number
- KR20030068205A KR20030068205A KR10-2003-7009205A KR20037009205A KR20030068205A KR 20030068205 A KR20030068205 A KR 20030068205A KR 20037009205 A KR20037009205 A KR 20037009205A KR 20030068205 A KR20030068205 A KR 20030068205A
- Authority
- KR
- South Korea
- Prior art keywords
- receptor
- antibody
- pharmaceutical composition
- monoclonal antibody
- binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01100507 | 2001-01-09 | ||
EP01100507.1 | 2001-01-09 | ||
PCT/EP2001/015241 WO2002055106A2 (fr) | 2001-01-09 | 2001-12-21 | Polytherapie faisant appel a des inhibiteurs de recepteurs tyrosine kinase et a des inhibiteurs d'angiogenese |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097006396A Division KR100983997B1 (ko) | 2001-01-09 | 2001-12-21 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20030068205A true KR20030068205A (ko) | 2003-08-19 |
Family
ID=8176174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097006396A KR100983997B1 (ko) | 2001-01-09 | 2001-12-21 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
KR10-2003-7009205A KR20030068205A (ko) | 2001-01-09 | 2001-12-21 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를사용하는 병용 요법 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020097006396A KR100983997B1 (ko) | 2001-01-09 | 2001-12-21 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
Country Status (17)
Country | Link |
---|---|
US (2) | US20040052785A1 (fr) |
EP (1) | EP1349574A2 (fr) |
JP (2) | JP4364510B2 (fr) |
KR (2) | KR100983997B1 (fr) |
CN (1) | CN100335132C (fr) |
AU (1) | AU2002219221B2 (fr) |
BR (1) | BR0116575A (fr) |
CA (1) | CA2436326C (fr) |
CZ (1) | CZ20031927A3 (fr) |
HK (1) | HK1060056A1 (fr) |
HU (1) | HUP0302544A3 (fr) |
MX (1) | MXPA03006121A (fr) |
PL (1) | PL206142B1 (fr) |
RU (1) | RU2292904C2 (fr) |
SK (1) | SK9072003A3 (fr) |
WO (1) | WO2002055106A2 (fr) |
ZA (1) | ZA200306125B (fr) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US7029652B2 (en) * | 1998-09-16 | 2006-04-18 | The Regents Of The University Of California | Method of treating tumors |
US8871279B2 (en) * | 2000-03-09 | 2014-10-28 | Yale University | Use of the combination of PHY906 and a tyrosine kinase inhibitor as a cancer treatment regimen |
ES2331646T3 (es) | 2000-05-19 | 2010-01-12 | Genentech, Inc. | Ensayo para la deteccion de genes para mejorar la probabilidad de una respuesta eficaz a una terapia contra el cancer basada en antagonistas de erbb. |
WO2002055106A2 (fr) * | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Polytherapie faisant appel a des inhibiteurs de recepteurs tyrosine kinase et a des inhibiteurs d'angiogenese |
PA8578001A1 (es) * | 2002-08-07 | 2004-05-07 | Warner Lambert Co | Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas |
MXPA05003796A (es) | 2002-10-10 | 2006-02-22 | Merck Patent Gmbh | Anticuerpos anti-erb-b biespecificos y su uso en terapia de tumor. |
AU2004282219C1 (en) * | 2003-10-15 | 2009-12-17 | Osi Pharmaceuticals, Inc. | Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors |
JP4832426B2 (ja) | 2004-04-02 | 2011-12-07 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 6,6−二環置換されたヘテロ二環式タンパク質キナーゼ阻害剤 |
NZ551355A (en) * | 2004-06-03 | 2009-09-25 | Hoffmann La Roche | Treatment of cancer with irinotecan (CPT-11) and erlotinib |
RU2006146623A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение оксалиплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
RU2006146612A (ru) | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
WO2006031689A2 (fr) * | 2004-09-13 | 2006-03-23 | Genzyme Corporation | Complexes multimeriques |
US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
PL1846030T3 (pl) | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
WO2006081985A1 (fr) * | 2005-02-04 | 2006-08-10 | F. Hoffmann-La Roche Ag | Traitement combine par un derive de n4-(oxycarbonyl substitue)-5'-desoxy-5-fluorocytidine et un inhibiteur de l'activite kinase du recepteur du facteur de croissance epidermique |
AU2006336468B2 (en) | 2005-02-11 | 2012-04-12 | University Of Southern California | Method of expressing proteins with disulfide bridges |
UA95902C2 (ru) | 2005-02-23 | 2011-09-26 | Дженентек, Инк. | Способ увеличения времени развития заболевания или выживаемости у раковых пациентов |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
US20110165150A1 (en) * | 2006-01-18 | 2011-07-07 | Merck Patent Gmbh | Isolated organ perfusion combination therapy of cancer |
WO2007084670A2 (fr) * | 2006-01-18 | 2007-07-26 | Merck Patent Gmbh | Traitement specifique utilisant des ligands de l’integrine destine a traiter un cancer |
US8008256B2 (en) * | 2006-05-01 | 2011-08-30 | University Of Southern California | Combination therapy for treatment of cancer |
WO2007139930A2 (fr) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Associations de médicaments comportant des urées de diaryle substituées pour le traitement du cancer |
EA017864B1 (ru) * | 2007-01-18 | 2013-03-29 | Мерк Патент Гмбх | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака |
US8450068B2 (en) * | 2007-02-16 | 2013-05-28 | University Of Virginia Patent Foundation | IgE antibodies to chimeric or humanized IgG therapeutic monoclonal antibodies as a screening test for anaphylaxis |
DE102007008419A1 (de) * | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
NZ578824A (en) | 2007-03-02 | 2012-03-30 | Genentech Inc | Predicting response to a her dimerisation inhibitor based on low her3 expression |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
EP2592156B1 (fr) | 2007-06-08 | 2016-04-20 | Genentech, Inc. | Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur HER2 |
EP3239178A1 (fr) | 2007-12-14 | 2017-11-01 | Bristol-Myers Squibb Company | Molécules de liaison au récepteur humain ox40 |
US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
US20110189206A1 (en) * | 2008-01-03 | 2011-08-04 | Barbas Iii Carlos F | Antibody Targeting Through a Modular Recognition Domain |
US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
JP2011510018A (ja) * | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
WO2010083495A2 (fr) * | 2009-01-18 | 2010-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Polypeptides ciblant le récepteur 2 du facteur de croissance de l'endothélium vasculaire (vegf) et l'intégrine alpha v bêta 3 |
EP2408479A1 (fr) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Plurithérapie contre le cancer comprenant l'administration d'un inhibiteur de l'egfr et d'un inhibiteur de l'igf-1r |
MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
CN102405214A (zh) | 2009-04-20 | 2012-04-04 | Osi药物有限责任公司 | C-吡嗪-甲胺的制备 |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
JP5705836B2 (ja) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター |
WO2011083391A2 (fr) | 2010-01-05 | 2011-07-14 | Pfizer Inc. | Biomarqueurs pour une thérapie du cancer par un anti-igf-1r |
WO2011087066A1 (fr) | 2010-01-14 | 2011-07-21 | 株式会社三和化学研究所 | Produit pharmaceutique destiné au traitement prophylactique ou thérapeutique de troubles accompagnés d'une angiogenèse oculaire et/ou d'une perméabilité vasculaire oculaire supérieure à la normale |
MX2012008958A (es) | 2010-02-18 | 2012-08-23 | Genentech Inc | Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer. |
RU2012151823A (ru) | 2010-05-04 | 2014-06-10 | Мерримак Фармасьютикалз, Инк. | Антитела против рецептора эпидермального фактора роста (egfr) и их применение |
WO2011146568A1 (fr) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Prédiction de réponses à un inhibiteur de her |
WO2012009705A1 (fr) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Complexes liant ang-2 et leurs utilisations |
HUE035554T2 (en) | 2010-08-06 | 2018-05-02 | Genzyme Corp | VEGF antagonist compositions and their uses |
RU2551963C2 (ru) | 2010-09-09 | 2015-06-10 | Пфайзер Инк. | Молекулы, связывающиеся с 4-1вв |
EP2643353A1 (fr) | 2010-11-24 | 2013-10-02 | Novartis AG | Molécules multi-spécifiques |
WO2012085111A1 (fr) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée |
EP2671589A4 (fr) | 2011-02-02 | 2014-11-19 | Public Univ Corp Nagoya City Univ | Agent médicinal pour la prévention ou le traitement de maladies associées à une néovascularisation intraoculaire et/ou une hyperperméabilité vasculaire intraoculaire |
WO2012129145A1 (fr) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Polythérapie du cancer du poumon non à petites cellules (nsclc) |
CN106432506A (zh) | 2011-05-24 | 2017-02-22 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
MX2014001766A (es) | 2011-08-17 | 2014-05-01 | Genentech Inc | Anticuerpos de neuregulina y sus usos. |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
WO2013081645A2 (fr) | 2011-11-30 | 2013-06-06 | Genentech, Inc. | Mutations dans erbb3 dans des cancers |
WO2013083810A1 (fr) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification de non-répondeurs aux inhibiteurs de her2 |
CN104220457A (zh) | 2012-03-27 | 2014-12-17 | 霍夫曼-拉罗奇有限公司 | 涉及her3抑制剂的诊断和治疗 |
EP3563865A3 (fr) | 2012-05-04 | 2019-12-04 | Pfizer Inc | Régimes immunothérapeutiques basés sur des antigènes associés à la prostate et un vaccin |
RU2692773C2 (ru) | 2012-11-30 | 2019-06-27 | Ф.Хоффманн-Ля Рош Аг | Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1 |
EP2968541A4 (fr) | 2013-03-15 | 2017-02-08 | Zyngenia, Inc. | Complexes multispécifiques multivalents et monovalents et leurs utilisations |
EP4091624A1 (fr) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Analogues d'hepcidine et leurs utilisations |
US20140294901A1 (en) * | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide dimer antagonists |
US20140294902A1 (en) * | 2013-04-02 | 2014-10-02 | Protagonist Therapeutics, Inc. | Novel a4b7 peptide antagonists |
KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
DK3143037T3 (da) | 2014-05-16 | 2021-09-20 | Protagonist Therapeutics Inc | Alpha4beta7-integrin-thioether-peptidantagonister |
RU2736637C9 (ru) | 2014-07-17 | 2021-02-08 | Протагонист Терепьютикс, Инк. | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника |
WO2016054445A1 (fr) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | Nouveaux peptides monomères et dimères cycliques possédant une activité antagoniste de l'intégrine |
JP2017535527A (ja) | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス, インコーポレイテッド | 新規のα4β7ペプチド単量体及び二量体拮抗薬 |
US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
CA3009834A1 (fr) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues de mimetiques d'hepcidine a demi-vie in vivo amelioree |
US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
WO2017194554A1 (fr) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Polythérapies pour le traitement du cancer |
WO2019036855A1 (fr) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Molécules anti-cd137 et leur utilisation |
CA3073806A1 (fr) | 2017-09-11 | 2019-03-14 | Protagonist Therapeutics, Inc. | Peptides d'agoniste opioide et leurs utilisations |
WO2019148444A1 (fr) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anticorps anti-ctla4 et leurs procédés de fabrication et d'utilisation |
WO2019148445A1 (fr) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation |
WO2019157268A1 (fr) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Mimétiques d'hepcidine conjugués |
TN2019000004A1 (fr) * | 2019-01-08 | 2020-07-15 | Ghidhaoui Abir | Vita, le traitement chimio thérapeutique pour plusieurs types de cancer et sans les effets indésirables majeurs et moyens. |
EP3997105A4 (fr) | 2019-07-10 | 2023-09-13 | Protagonist Therapeutics, Inc. | Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires |
CN118005737A (zh) | 2020-01-15 | 2024-05-10 | 詹森生物科技公司 | 介白素-23受体的肽抑制剂及其治疗炎性疾病的用途 |
CA3202226A1 (fr) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Compositions d'inhibiteurs peptidiques du recepteur de l'interleukine-23 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5342945A (en) * | 1986-12-02 | 1994-08-30 | University Of Florida Research Foundation, Inc. | Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives |
US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
HU219537B (hu) * | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US7053041B1 (en) * | 1996-05-31 | 2006-05-30 | The Scripps Research Institute | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis |
DE19534177A1 (de) * | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
DE19842415A1 (de) * | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
IL126953A0 (en) * | 1998-11-08 | 1999-09-22 | Yeda Res & Dev | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
AU8986501A (en) * | 2000-09-08 | 2002-03-22 | Pharmacia & Upjohn Spa | Exemestane as chemopreventing agent |
WO2002055106A2 (fr) * | 2001-01-09 | 2002-07-18 | Merck Patent Gmbh | Polytherapie faisant appel a des inhibiteurs de recepteurs tyrosine kinase et a des inhibiteurs d'angiogenese |
MXPA05003796A (es) * | 2002-10-10 | 2006-02-22 | Merck Patent Gmbh | Anticuerpos anti-erb-b biespecificos y su uso en terapia de tumor. |
-
2001
- 2001-12-21 WO PCT/EP2001/015241 patent/WO2002055106A2/fr active IP Right Grant
- 2001-12-21 JP JP2002555839A patent/JP4364510B2/ja not_active Expired - Fee Related
- 2001-12-21 KR KR1020097006396A patent/KR100983997B1/ko not_active IP Right Cessation
- 2001-12-21 SK SK907-2003A patent/SK9072003A3/sk unknown
- 2001-12-21 CZ CZ20031927A patent/CZ20031927A3/cs unknown
- 2001-12-21 PL PL362407A patent/PL206142B1/pl unknown
- 2001-12-21 EP EP01273120A patent/EP1349574A2/fr not_active Withdrawn
- 2001-12-21 RU RU2003123781/15A patent/RU2292904C2/ru not_active IP Right Cessation
- 2001-12-21 BR BR0116575-5A patent/BR0116575A/pt not_active IP Right Cessation
- 2001-12-21 HU HU0302544A patent/HUP0302544A3/hu unknown
- 2001-12-21 MX MXPA03006121A patent/MXPA03006121A/es active IP Right Grant
- 2001-12-21 CN CNB018218784A patent/CN100335132C/zh not_active Expired - Fee Related
- 2001-12-21 AU AU2002219221A patent/AU2002219221B2/en not_active Ceased
- 2001-12-21 CA CA2436326A patent/CA2436326C/fr not_active Expired - Fee Related
- 2001-12-21 US US10/250,783 patent/US20040052785A1/en not_active Abandoned
- 2001-12-21 KR KR10-2003-7009205A patent/KR20030068205A/ko not_active Application Discontinuation
-
2003
- 2003-08-07 ZA ZA2003/06125A patent/ZA200306125B/en unknown
-
2004
- 2004-04-29 HK HK04103020A patent/HK1060056A1/xx not_active IP Right Cessation
-
2008
- 2008-12-19 JP JP2008323085A patent/JP2009102359A/ja active Pending
-
2010
- 2010-09-15 US US12/882,541 patent/US20110223167A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2009102359A (ja) | 2009-05-14 |
KR20090038037A (ko) | 2009-04-17 |
WO2002055106A2 (fr) | 2002-07-18 |
SK9072003A3 (en) | 2003-11-04 |
US20110223167A1 (en) | 2011-09-15 |
CN100335132C (zh) | 2007-09-05 |
PL206142B1 (pl) | 2010-07-30 |
HUP0302544A2 (hu) | 2003-10-28 |
WO2002055106A3 (fr) | 2003-03-06 |
PL362407A1 (en) | 2004-11-02 |
AU2002219221B2 (en) | 2007-05-17 |
CA2436326C (fr) | 2012-08-14 |
BR0116575A (pt) | 2004-01-06 |
CZ20031927A3 (cs) | 2003-10-15 |
JP2004520344A (ja) | 2004-07-08 |
RU2292904C2 (ru) | 2007-02-10 |
JP4364510B2 (ja) | 2009-11-18 |
CN1486191A (zh) | 2004-03-31 |
CA2436326A1 (fr) | 2002-07-18 |
HUP0302544A3 (en) | 2012-09-28 |
US20040052785A1 (en) | 2004-03-18 |
MXPA03006121A (es) | 2003-09-10 |
KR100983997B1 (ko) | 2010-09-28 |
EP1349574A2 (fr) | 2003-10-08 |
HK1060056A1 (en) | 2004-07-30 |
ZA200306125B (en) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100983997B1 (ko) | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 | |
KR101088661B1 (ko) | Erb-b1 수용체를 표적으로 하는 약학적 조성물 | |
AU2002219221A1 (en) | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors | |
AU2002315306B2 (en) | Combination therapy using anti-EGFR antibodies and anti-hormonal agents | |
KR100861466B1 (ko) | 항혈관형성제 및 TNFα를 이용한 병용 요법 | |
AU2002315306A1 (en) | Combination therapy using anti-EGFR antibodies and anti-hormonal agents | |
KR20080089645A (ko) | 암의 적출 장기 관류 병용 요법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090227 Effective date: 20100826 |
|
WITB | Written withdrawal of application |